Latest announcements from THREAD
New platform capabilities help sponsors and CROs standardize participant, device, and operational data from any source to identify risks earlier, automate workflows, and improve decentralized and hybrid trial execution.
Platform enhancement provides Sponsors/CROs a novel, configurable approach for complex cohorts in basket trials, umbrella trials, and multi-arm studies
Peer-reviewed publication highlights the power and depth of insights from patient voice data in dermatology research and care innovation
Built from expertise gained in proven AI solutions and a decade of inVibe voice interview experience, AI Moderator securely guides patients and HCPs to offer their voice insights via AI-responsive interviews
New benchmarks demonstrate novel capabilities becoming the standard for large-scale voice insights enabling rapid co-creation with stakeholders by biopharma
New platform features empower THREAD to transition active clinical trials from other technologies and integrate data from any source via a configurable migration solution
Collaboration Adds THREAD’s Technology and Enablement Services Focused on Reducing Patient Clinic Visitations with Innovative Remote Monitoring Solution
THREAD Configurable SaaS Technology Awarded DiMe Seal in Inaugural Batch
Enhanced from experience supporting the most complex research environments in more than 60 countries and 100 languages, THREAD introduces the next major release of their platform with the industry’s most comprehensive set of advanced, fully configurable features
THREAD integrates Anthropic’s Claude large language models (LLMs) via Amazon Bedrock to enhance patient feedback analysis, delivering comprehensive patient voice data summaries through automated presentations
Thread partners with Allucent on their award with BARDA’s innovative research program
Collaboration Pioneers No-code, Fully Configurable eClinical Technology for Academic Research at Enterprise Scale
Biopharma sponsorsand CROs now have access to a modern eCOA solution that seamlessly integrates a configurable, no-code platform with validated cognitive assessments and deep clinical expertise
Collaboration augments full-featured central site model with additional research services and technology to widen recruitment access and improve the site and patient experience
Offering Biopharmaceutical companies and CROs an Innovative Solution to Collect and Integrate Prospective Study Data with Retrospective Real-World Data for Research
Provides Research Sites and Study Teams with Enhanced, Unified Log-in Experience
THREAD® today announced the appointment of Kim Boericke as a chief delivery officer. In this role, Boericke will lead the company’s Technology Enablement Consulting Services.
Bezyl, Inc., a global, digital mental health company, announced today that it is collaborating with THREAD® to provide its mental health digital app and support system to patients participating in clinical trials.
This partnership solidifies MMS as a full-service DCT provider, from electronic data capture (EDC) through completion of the DCT. THREAD offers a flexible approach to clinical research sponsors who want a DCT offering that is easily accessible and not tied to any particular EDC system.
Headquartered in Costa Mesa, Calif., CureClick offers the world’s first proprietary crowdsourcing platform designed exclusively to accelerate awareness and participation in clinical research. CureClick follows THREAD’s recent acquisitions of Modus Outcomes and inVibe, positioning THREAD as the industry’s leading patient-centric provider of DCTs.
As clinical trials and real-world research have grown more complex, experts have challenged the industry to bring the patient voice into research studies in one platform. THREAD's new offering addresses these needs by providing actionable intelligence for customers focused on real-world patient experience.
As chief product officer, Pearson will lead THREAD’s product teams to advance the company’s mission of providing customers with one comprehensive global platform, delivering products to support research that is five times more inclusive and enabling decentralized clinical trials that are 30 percent more efficient.
THREAD, a leading technology and service provider enabling decentralized clinical trials (DCTs), today announced that it has acquired Modus Outcomes to combine high-technology and high-science in one platform designed to achieve higher-quality outcomes for research sponsors.
THREAD announced the company’s expansion into the Europe, Middle East and Africa (EMEA) region to support location-specific clinical trials and meet the increased demand for global studies.
New consulting service enables a repeatable, scalable pathway for migrating future studies to global decentralized research approach.
Integration of data capture and transactions ensures that the site and subject stay together in a unified workflow.
Worldwide analyst Everest Group acknowledges THREAD’s global expertise.
The market leaders will integrate their technologies to enable more efficient clinical trials that generate better outcomes.
Prestigious honor highlights THREAD’s excellence in the decentralized clinical trials industry.
New, comprehensive in-home visit solution provides seamless digital experiences for clients and patients for decentralized clinical trials.
THREAD’s new offering combines the company’s proprietary technology, deep regulatory knowledge and experience supporting organizations with hundreds of clinical studies utilizing a global decentralized trial approach.
New solution provides descriptive key performance indicators, predictive measures and actionable insights to drive informed decision-making and optimized study performance.
Innovative collaboration streamlines global recruitment processes and maximizes opportunities for DCT inclusivity for trial participants.
Strategic alliance will streamline patient-centric recruitment for sponsors and CROs, ultimately improving recruitment and retention outcomes in decentralized clinical trials.
THREAD joins the Decentralized Trials & Research Alliance (DTRA), a formidable alliance of over 50 life sciences and healthcare organizations, to accelerate the broad adoption of patient-focused decentralized clinical trials and research.
THREAD accelerates its expansion after receiving an additional capital commitment of up to $50 million from strategic health care investors, Water Street Healthcare Partners and JLL Partners.
THREAD partners with its biopharma and CRO customers through a specialized offering called THREAD Express to rapidly support study-specific COVID-19 risk mitigation plans.
Water Street Healthcare Partners and JLL Partners acquire THREAD, an innovative provider of technology that enables virtual research approaches to modernize clinical studies and registries.